Tenacia Biotechnology

Privately held: no public share price · Hong Kong

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
AMPA receptor (TARP γ8-dependent)Small molecule
Epilepsy
Focal Onset Seizures

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
February 2028 (1)
RAP-219Phase 2Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure
Est. primary completion 2028-02-03 · NCT07219407 · CT.gov ↗
What to watch
2029 (2)
July 2029 (2)
RAP-219Phase 3Focal Seizure, Epilepsy, Focal Epilepsy
Est. primary completion 2029-07 · NCT07563881 · CT.gov ↗
What to watch
RAP-219Phase 3Focal Seizure, Epilepsy, Focal Epilepsy
Est. primary completion 2029-07 · NCT07594119 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

20 October 2026Topline resultRAP-219Phase 2 of RAP-219 in bipolar mania met its primary endpoint
Rapport Therapeutics, Inc. · Source ↗
8 September 2025Topline resultRAP-219Phase 2a RAP-219-FOS-201 of RAP-219 in focal onset seizures: positive topline results
Rapport Therapeutics, Inc. · Source ↗

Financial reports

No financial reports recorded.